Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending March 28, 2007. The report serves as a notification of transactions involving Directors, Persons Discharging Managerial Responsibility, or Connected Persons regarding the Company's Ordinary Shares and American Depositary Receipts (ADRs).
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This document is a regulatory notification of share transactions rather than a financial performance report.
Material Changes
The filing details a specific transaction on March 26, 2007, where Abacus (GSK) Trustees Limited, acting as trustee for the GlaxoSmithKline Employee Trust, transferred 11,002 Ordinary Shares to participants in the SmithKline Beecham Employee Share Option Plan 1991. The Company was advised of these transactions on March 27, 2007.
Guidance, Outlook, and Risks
The filing contains no management commentary, financial guidance, outlook, or discussion of risks and contingencies. It strictly addresses the notification of the share transfer in accordance with Disclosure Rule 3.1.4R(1)(b). The GSK Trust is identified as a discretionary trust where all current and former employees are potential beneficiaries.
Key Facts for Investor Verification
- 11,002 Ordinary Shares were transferred from the GSK Trust to employee plan participants on March 26, 2007.
- Directors Dr JP Garnier, Dr M M Slaoui, and Mr J S Heslop hold interests in the GSK Trust shares in the same capacity as other employees.
- This filing does not contain financial performance data for the period.